Price
Financials
Consolidated, Rs crore| Mar 2025 | Mar 2026 | |
|---|---|---|
| Sales | 217 | 198 |
| Expenses | 172 | 136 |
| Operating Profit | 45 | 62 |
| OPM % | 21% | 31% |
| Other Income | -11 | 2 |
| Interest | 8 | 11 |
| Depreciation | 3 | 7 |
| Profit before tax | 22 | 46 |
| Tax % | 71% | 26% |
| Net Profit | 9 | 34 |
| EPS in Rs | 56.13 | 21.14 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales | 183 | 203 | 314 | 342 |
| Expenses | 149 | 165 | 239 | 244 |
| Operating Profit | 34 | 38 | 75 | 98 |
| OPM % | 18% | 19% | 24% | 29% |
| Other Income | 2 | 3 | -8 | 5 |
| Interest | 4 | 6 | 15 | 19 |
| Depreciation | 2 | 4 | 7 | 11 |
| Profit before tax | 30 | 31 | 44 | 73 |
| Tax % | 28% | 29% | 45% | 23% |
| Net Profit | 32 | 34 | 28 | 56 |
| EPS in Rs | 203.81 | 218.67 | 178.60 | 34.24 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | % | 23% | 9% | ||
| Compounded Profit Growth | % | % | 21% | 25% | ||
| Stock Price CAGR | % | % | % | % | ||
| Return on Equity | % | % | 25% | 26% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 16 |
| Reserves | 126 | 160 | 188 | 230 |
| Borrowings | 74 | 97 | 166 | 225 |
| Other Liabilities | 51 | 81 | 99 | 87 |
| Total Liabilities | 252 | 339 | 455 | 559 |
| Fixed Assets | 23 | 60 | 92 | 145 |
| CWIP | 12 | 19 | 63 | 15 |
| Investments | 16 | 29 | 0 | 17 |
| Other Assets | 201 | 232 | 301 | 381 |
| Total Assets | 252 | 339 | 455 | 559 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from Operating Activity | 25 | -24 | -1 | 16 |
| Cash from Investing Activity | -26 | -45 | -59 | -29 |
| Cash from Financing Activity | 26 | 17 | 53 | 42 |
| Net Cash Flow | 25 | -52 | -7 | 29 |
| Free Cash Flow | -5 | -72 | -58 | -19 |
| CFO/OP | 111% | -39% | 7% | 43% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 66 | 47 | 96 | 134 |
| Inventory Days | 180 | 413 | 226 | 258 |
| Days Payable | 164 | 232 | 139 | 142 |
| Cash Conversion Cycle | 82 | 228 | 183 | 251 |
| Working Capital Days | -44 | 51 | 45 | 62 |
| ROCE % | 16% | 25% | 22% |
| May 2026 | |
|---|---|
| Promoters | 67.51% |
| FIIs | 1.67% |
| DIIs | 10.14% |
| Public | 20.67% |
| No. of Shareholders | 3,497 |
Fundamentals
Market Cap₹ 1,569 Cr.
Current Price₹ 673
Stock P/E27.8
Book Value₹
ROCE22.5 %
ROE25.9 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)9%
Compounded Profit Growth (TTM)25%
Consolidated figures.
Ownership
Promoter holding67.51%
Computed by MarketFriction from the consolidated statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | QLINE | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -2.0% | -2.8% | +0.7 pts |
| 1 month | +12.6% | -6.8% | +19.4 pts |
| 3 months | +15.4% | -7.6% | +23.0 pts |
1 mutual fund schemes hold about ₹29 Cr.
Over three months 0 bought more and 0 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| Abakkus Small Cap Fund | 1.05% | 29 |
Red flags
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
No quarterly results published.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Poly Medicure Ltd | 16,671 | 52.1 | 12.5 % |
| Molbio Diagnostics Ltd | 14,470 | 66.6 | 18.0 % |
| Fischer Medical Ventures Ltd | 2,355 | 96.2 | 11.4 % |
| Tarsons Products Ltd | 1,754 | 148 | 4.59 % |
| Laxmi Dental Ltd | 1,058 | 30.4 | 15.0 % |
| Hemant Surgical Industries Ltd | 869 | 51.3 | 18.9 % |
| Vasa Denticity Ltd | 754 | 62.3 | 7.54 % |
| OSEL Devices Ltd | 691 | 23.6 | 24.4 % |
| Prevest Denpro Ltd | 462 | 20.5 | 24.9 % |
| QMS Medical Allied Services Ltd | 419 | 39.0 | 12.9 % |
| Nureca Ltd | 349 | 80.4 | 3.30 % |
| Aprameya Engineering Ltd | 200 | 39.7 | 12.6 % |
| Avience Biomedicals Ltd | 198 | 22.7 | 27.0 % |
| Earkart Limited | 179 | 36.3 | 17.5 % |
| Vaidya Sane Ayurved Laboratories Ltd | 176 | 19.6 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
SME scrip is not regularly traded
Quick answers
What is the market cap of Q-Line Biotech Ltd?
Q-Line Biotech Ltd (QLINE) has a market capitalisation of Rs 1,569 Cr. at the 2026-10-01 close.
What is the P/E ratio of Q-Line Biotech Ltd?
Q-Line Biotech Ltd trades at a P/E of 27.8 on trailing twelve-month profit, at the 2026-10-01 close.
What is the 52-week high and low of Q-Line Biotech Ltd?
The 52-week high is Rs 735.00 and the 52-week low is Rs 431.00.